[Tiagabine in drug-resistant epilepsy in children: preliminary study].

Abstract

UNLABELLED:

The aim of the study was the presentation of our preliminary experiences and the data concerning the efficacy and safety of tiagabine in patients below the 12-th year of life. 4 cases of drug--resistant epilepsy--with partial complex attacks in 3 and simple in 1 (frontal epilepsy from supplementary motor area) with multiple seizures in the day were the subject of the study. Tiagabine add-one therapy to CBZ or to VPA was used. Initial period--the dose titration lasted 4 weeks. The stable dosis period amounted to 5 months. The effective dosis of tiagabine was 1 mg/kg/day. In 1 case the seizures completely disappeared and in 3 the frequency decreased to 2-4 times in comparison to frequency per day before the treatment. There were not any side-effects reported which would be the cause of the drug discontinuation.

IN CONCLUSION:

Tiagabine appeared to be an effective and safe drug in resistant epilepsy in children below 12 years of age.

• Authors: J Wendorff, M Popielarczyk, M Zubiel, D Sokołowska
• Journal: Neurologia i neurochirurgia polska (Neurol Neurochir Pol) Vol. 34 Suppl 1 Pg. 221-4 ( 2000) ISSN: 0028-3843 [Print] Poland
• Vernacular Title: Tiagabina w lekoopornej padaczce u dzieci--doświadczenia wstepne.
• PMID: 10768162 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anticonvulsants
• Nipecotic Acids
• Tiagabine

Topics

• Anticonvulsants (therapeutic use)
• Child
• Child, Preschool
• Dose-Response Relationship, Drug
• Drug Resistance
• Epilepsy (drug therapy)
• Female
• Humans
• Male
• Nipecotic Acids (therapeutic use)
• Tiagabine
• Treatment Outcome